Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome
| Autor: | Abdulkarim Al-Makdama, Samhar Al-Akash |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Nephrotic Syndrome Time Factors Frequently Relapsing Nephrotic Syndrome lcsh:Medicine Mycophenolate Recurrence Risk Factors medicine Humans Child Glomerular diseases Retrospective Studies business.industry lcsh:R Anti-Inflammatory Agents Non-Steroidal Infant General Medicine Mycophenolic Acid Steroid dependency Treatment Outcome Child Preschool Female business Immunosuppressive Agents Follow-Up Studies |
| Zdroj: | Annals of Saudi Medicine, Vol 25, Iss 5, Pp 380-384 (2005) |
| ISSN: | 0256-4947 |
| Popis: | Background: Mycophenolate mofetil (MMF) has emerged as a new agent for treatment of a variety of glomerular diseases. This study ex-amines the safety and efficacy of MMF in treating pediatric patients with steroid-dependent (SD) and/or frequently relapsing (FR) nephrotic syndrome (NS). Methods: We retrospectively reviewed the medical records of 18 pa-tients with SDNS and/or FRNS treated with MMF for at least 3 months. MMF was used in 11 patients with SDNS (n=10) and FRNS (n=1), includ-ing 7 males and 4 females. Results: Mean age at time of diagnosis of NS was 3.3 years (range, 1.1-8.5 years), and at the start of MMF 5.9 years (range, 2.9-10 years). Seven patients had a renal biopsy prior to starting MMF; all had me-sangial proliferative glomerulonephritis. Mean follow-up after starting MMF was 12.2 months (range, 4-24 months). Mean MMF dose was 948 mg/m2/day (range, 500-1087 mg/m2/day). MMF resulted in improvement in 9 of 11 patients, with 8 patients weaned off steroids completely, with a reduction in the mean relapse rate from 4.7 relapses/patient/year (range, 2.4-6) before MMF to 1.05 relapses/patient/year (range, 0-4.5) after MMF therapy (P=0.0001). The relative risk for relapse before MMF was 4.7 (P=0.0002). None of the patients had significant adverse events or intol-erance to MMF therapy. Conclusion: We conclude that MMF is a safe and effective option for treatment of children with SDNS and/or FRNS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|